(Q38832525)

6 September 2017

1 reference

title

International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma (English)

1 reference

6 September 2017

40

Herve Avet-Loiseau

0 references

Efstathios Kastritis

Efstathios Kastritis

12

0 references

Hans Erik Johnsen

Hans E Johnsen

23

0 references

Athanasios Dimopoulos

Meletios Dimopoulos

11

0 references

Robert A Kyle

26

Robert A Kyle

1 reference

6 September 2017

8

Sagar Lonial

1 reference

6 September 2017

5

Ola Landgren

1 reference

6 September 2017

3

Kenneth C Anderson

1 reference

6 September 2017

27

Pieter Sonneveld

1 reference

6 September 2017

28

Paul G Richardson

1 reference

6 September 2017

15

Hartmut Goldschmidt

1 reference

6 September 2017

38

S Vincent Rajkumar

1 reference

6 September 2017

36

Antonio Palumbo

1 reference

6 September 2017

6

Philippe Moreau

1 reference

6 September 2017

30

Heinz Ludwig

1 reference

6 September 2017

14

Robert Orlowski

1 reference

6 September 2017

37

Alberto Orfao

1 reference

6 September 2017

1

Shaji Kumar

1 reference

6 September 2017

29

Philip McCarthy

1 reference

6 September 2017

39

Jesus San Miguel

1 reference

6 September 2017

24

Evangelos Terpos

1 reference

6 September 2017

7

Nikhil Munshi

1 reference

6 September 2017

35

Jens Hillengass

1 reference

6 September 2017

2

Bruno Paiva

1 reference

6 September 2017

20

Elena Zamagni

1 reference

6 September 2017

19

Saad Z Usmani

1 reference

6 September 2017

María Victoria Mateos

10

Maria-Victoria Mateos

1 reference

6 September 2017

9

Joan Bladé

1 reference

6 September 2017

13

Mario Boccadoro

1 reference

6 September 2017

32

Michele Cavo

1 reference

6 September 2017

22

Sundar Jagannath

1 reference

6 September 2017

25

Anthony Reiman

1 reference

6 September 2017

33

Jean-Luc Harousseau

1 reference

6 September 2017

18

Wee Joo Chng

1 reference

6 September 2017

34

Suzanne Lentzsch

1 reference

6 September 2017

4

Brian Durie

1 reference

6 September 2017

Andrew Spencer

16

1 reference

6 September 2017

Jian Hou

17

1 reference

6 September 2017

Kazuyuki Shimizu

21

1 reference

6 September 2017

Wenming Chen

31

1 reference

6 September 2017

publication date

1 August 2016

1 reference

Lancet Oncology Commission

6 September 2017

published in

1 reference

6 September 2017

volume

17

1 reference

6 September 2017

issue

8

1 reference

6 September 2017

page(s)

e328-e346

1 reference

Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients.

6 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930206-6

7 January 2021

Survival of multiple myeloma patients in the era of novel therapies confirms the improvement in patients younger than 75 years: a population-based analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930206-6

7 January 2021

IV. Initial treatment of multiple myeloma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930206-6

7 January 2021

Clinical translation in multiple myeloma: from bench to bedside

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930206-6

7 January 2021

Multiple myeloma: future directions in autologous transplantation and novel agents

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930206-6

7 January 2021

Myeloma: classification and risk assessment.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930206-6

7 January 2021

IMWG consensus on risk stratification in multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930206-6

7 January 2021

International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930206-6

7 January 2021

International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple Myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930206-6

7 January 2021

International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930206-6

7 January 2021

International uniform response criteria for multiple myeloma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930206-6

7 January 2021

The importance of bone marrow examination in determining complete response to therapy in patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930206-6

7 January 2021

Importance of achieving stringent complete response after autologous stem-cell transplantation in multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930206-6

7 January 2021

Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930206-6

7 January 2021

A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930206-6

7 January 2021

High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930206-6

7 January 2021

Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930206-6

7 January 2021

Lenalidomide after stem-cell transplantation for multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930206-6

7 January 2021

A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930206-6

7 January 2021

Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930206-6

7 January 2021

Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised p

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930206-6

7 January 2021

Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930206-6

7 January 2021

Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy: analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930206-6

7 January 2021

Importance of achieving a complete response in multiple myeloma, and the impact of novel agents

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930206-6

7 January 2021

The role of complete response in multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930206-6

7 January 2021

A multiparameter flow cytometry immunophenotypic algorithm for the identification of newly diagnosed symptomatic myeloma with an MGUS-like signature and long-term disease control

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930206-6

7 January 2021

Complete response correlates with long-term survival and progression-free survival in high-dose therapy in multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930206-6

7 January 2021

Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930206-6

7 January 2021

Comparison of immunofixation, serum free light chain, and immunophenotyping for response evaluation and prognostication in multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930206-6

7 January 2021

High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930206-6

7 January 2021

Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930206-6

7 January 2021

Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930206-6

7 January 2021

Critical evaluation of ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma. A comparative analysis with flow cytometry.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930206-6

7 January 2021

Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930206-6

7 January 2021

Is this the time to introduce minimal residual disease in multiple myeloma clinical practice?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930206-6

7 January 2021

Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930206-6

7 January 2021

Kappa deleting element as an alternative molecular target for minimal residual disease assessment by real-time quantitative PCR in patients with multiple myeloma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930206-6

7 January 2021

Evaluation of minimal residual disease in multiple myeloma patients by fluorescent-polymerase chain reaction: the prognostic impact of achieving molecular response.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930206-6

7 January 2021

Real-Time polymerase chain reaction of immunoglobulin rearrangements for quantitative evaluation of minimal residual disease in multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930206-6

7 January 2021

EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930206-6

7 January 2021

EuroFlow standardization of flow cytometer instrument settings and immunophenotyping protocols

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930206-6

7 January 2021

Multiparameter flow cytometry quantification of bone marrow plasma cells at diagnosis provides more prognostic information than morphological assessment in myeloma patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930206-6

7 January 2021

Novel multi-parameter flow cytometry sensitively detects phenotypically distinct plasma cell subsets in plasma cell proliferative disorders

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930206-6

7 January 2021

Immunophenotypic evaluation of the plasma cell compartment in multiple myeloma: a tool for comparing the efficacy of different treatment strategies and predicting outcome.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930206-6

7 January 2021

Flow cytometric disease monitoring in multiple myeloma: the relationship between normal and neoplastic plasma cells predicts outcome after transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930206-6

7 January 2021

Prognostic Value of Immunophenotyping in Multiple Myeloma: A Study by the PETHEMA/GEM Cooperative Study Groups on Patients Uniformly Treated With High-Dose Therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930206-6

7 January 2021

Clinical significance of CD81 expression by clonal plasma cells in high-risk smoldering and symptomatic multiple myeloma patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930206-6

7 January 2021

New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930206-6

7 January 2021

PD-L1/PD-1 presence in the tumor microenvironment and activity of PD-1 blockade in multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930206-6

7 January 2021

Review of phenotypic markers used in flow cytometric analysis of MGUS and MM, and applicability of flow cytometry in other plasma cell disorders.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930206-6

7 January 2021

Consensus guidelines for myeloma minimal residual disease sample staining and data acquisition

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930206-6

7 January 2021

Minimal residual disease testing in multiple myeloma by flow cytometry: major heterogeneity

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930206-6

7 January 2021

Assessment of minimal residual disease in myeloma and the need for a consensus approach

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930206-6

7 January 2021

Complete remission sustained 3 years from treatment initiation is a powerful surrogate for extended survival in multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930206-6

7 January 2021

Front-line transplantation program with lenalidomide, bortezomib, and dexamethasone combination as induction and consolidation followed by lenalidomide maintenance in patients with multiple myeloma: a phase II study by the Intergroupe Francophone du

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930206-6

7 January 2021

Minimal residual disease diagnostics in acute lymphoblastic leukemia: need for sensitive, fast, and standardized technologies

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930206-6

7 January 2021

New criteria for response assessment: role of minimal residual disease in multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930206-6

7 January 2021

The level of minimal residual disease in the bone marrow of patients with multiple myeloma before high-dose therapy and autologous blood stem cell transplantation is an independent predictive parameter

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930206-6

7 January 2021

Depth of response assessed by quantitative ASO-PCR predicts the outcome after stem cell transplantation in multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930206-6

7 January 2021

Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930206-6

7 January 2021

Molecular remission after allogeneic or autologous transplantation of hematopoietic stem cells for multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930206-6

7 January 2021

Post-transplantation tumour load in bone marrow, as assessed by quantitative ASO-PCR, is a prognostic parameter in multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930206-6

7 January 2021

Molecular monitoring of the tumor load predicts progressive disease in patients with multiple myeloma after high-dose therapy with autologous peripheral blood stem cell transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930206-6

7 January 2021

Prognostic role of minimal residual disease in multiple myeloma patients after non-myeloablative allogeneic transplantation.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930206-6

7 January 2021

Clinical applicability and prognostic significance of molecular response assessed by fluorescent-PCR of immunoglobulin genes in multiple myeloma. Results from a GEM/PETHEMA study.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930206-6

7 January 2021

The use of CD138 positively selected marrow samples increases the applicability of minimal residual disease assessment by PCR in patients with multiple myeloma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930206-6

7 January 2021

Minimal Residual Disease Detection by Droplet Digital PCR in Multiple Myeloma, Mantle Cell Lymphoma, and Follicular Lymphoma: A Comparison with Real-Time PCR.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930206-6

7 January 2021

Next-generation sequencing and real-time quantitative PCR for minimal residual disease detection in B-cell disorders.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930206-6

7 January 2021

Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930206-6

7 January 2021

Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930206-6

7 January 2021

Extramedullary involvement in multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930206-6

7 January 2021

Incidence of extramedullary disease in patients with multiple myeloma in the era of novel therapy, and the activity of pomalidomide on extramedullary myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930206-6

7 January 2021

Incidence, presenting features and outcome of extramedullary disease in multiple myeloma: a longitudinal study on 1003 consecutive patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930206-6

7 January 2021

p53 nuclear accumulation is associated with extramedullary progression of multiple myeloma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930206-6

7 January 2021

Plasmacytoma of bone, extramedullary plasmacytoma, and multiple myeloma: incidence and survival in the United States, 1992-2004.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930206-6

7 January 2021

Prognostic implications of serial 18-fluoro-deoxyglucose emission tomography in multiple myeloma treated with total therapy 3

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930206-6

7 January 2021

F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930206-6

7 January 2021

¹⁸F-fluoro-deoxyglucose positron emission tomography in assessment of myeloma-related bone disease: a systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930206-6

7 January 2021

Combining FDG-PET/CT with laboratory data yields superior results for prediction of relapse in multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930206-6

7 January 2021

PET/CT Improves the Definition of Complete Response and Allows to Detect Otherwise Unidentifiable Skeletal Progression in Multiple Myeloma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930206-6

7 January 2021

Challenges and opportunities of novel imaging techniques in monoclonal plasma cell disorders: imaging "early myeloma".

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930206-6

7 January 2021

Magnetic resonance imaging in multiple myeloma: diagnostic and clinical implications

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930206-6

7 January 2021

Changes in magnetic resonance imaging before and after autologous stem cell transplantation correlate with response and survival in multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930206-6

7 January 2021

Role of magnetic resonance imaging in the management of patients with multiple myeloma: a consensus statement

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930206-6

7 January 2021

Comparative diagnostic performance of ¹⁸F-FDG PET/CT versus whole-body MRI for determination of remission status in multiple myeloma after stem cell transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930206-6

7 January 2021

Imaging of multiple myeloma and related plasma cell dyscrasias

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930206-6

7 January 2021

18F-FDG PET/CT for detection and localization of residual or recurrent disease in patients with multiple myeloma after stem cell transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930206-6

7 January 2021

Whole-Body MRI versus PET in assessment of multiple myeloma disease activity

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930206-6

7 January 2021

Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930206-6

7 January 2021

The prognostic value of multiparameter flow cytometry minimal residual disease assessment in relapsed multiple myeloma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930206-6

7 January 2021

Image interpretation criteria for FDG PET/CT in multiple myeloma: a new proposal from an Italian expert panel. IMPeTUs (Italian Myeloma criteria for PET USe).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930206-6

7 January 2021

Clinical and research applications of simultaneous positron emission tomography and MRI

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930206-6

7 January 2021

Whole-body diffusion-weighted MRI: a new gold standard for assessing disease burden in patients with multiple myeloma?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930206-6

7 January 2021

Interference of monoclonal antibody therapies with serum protein electrophoresis tests

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930206-6

7 January 2021

Detection of a monoclonal antibody therapy (ofatumumab) by serum protein and immunofixation electrophoresis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930206-6

7 January 2021

Detecting monoclonal immunoglobulins in human serum using mass spectrometry.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930206-6

7 January 2021

The antigenic landscape of multiple myeloma: mass spectrometry (re)defines targets for T-cell-based immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930206-6

7 January 2021

Circulating plasma cells detected by flow cytometry as a predictor of survival in 302 patients with newly diagnosed multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930206-6

7 January 2021

Quantification of clonal circulating plasma cells in relapsed multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930206-6

7 January 2021

Quantification of clonal circulating plasma cells in newly diagnosed multiple myeloma: implications for redefining high-risk myeloma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930206-6

7 January 2021

Molecular monitoring of minimal residual disease in the peripheral blood of patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930206-6

7 January 2021

Deep sequencing reveals myeloma cells in peripheral blood in majority of multiple myeloma patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930206-6

7 January 2021

Prognostic Impact of Serum Immunoglobulin Heavy/Light Chain Ratio in Patients with Multiple Myeloma in Complete Remission after Autologous Stem Cell Transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930206-6

7 January 2021

Immunoglobulin heavy/light chain ratios improve paraprotein detection and monitoring, identify residual disease and correlate with survival in multiple myeloma patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930206-6

7 January 2021

High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930206-6

7 January 2021

Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930206-6

7 January 2021

Comparison of serum free light chain and urine electrophoresis for the detection of the light chain component of monoclonal immunoglobulins in light chain and intact immunoglobulin multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930206-6

7 January 2021

International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930206-6

7 January 2021

Appraisal of immunoglobulin free light chain as a marker of response

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930206-6

7 January 2021

10.1016/S1470-2045(16)30206-6

Identifiers

DOI

1 reference

6 September 2017

1 reference